MK-2206 is an inhibitor of Akt in the PI3K/Akt/mTOR pathway, and a multicenter phase II clinical study has demonstrated that its combination with neoadjuvant therapy can improve the pathological complete response (pCR) rate of HR-negative and HER2-positive breast cancer [55]. This evidence concerns the gene ERBB2 and breast carcinoma.